title: Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.
abstract: Docetaxel is the current first line therapy for metastatic castration-resistant prostate cancer (mCRPC), but there is no standard number of docetaxel cycles given to patients. In their post hoc analysis of the Mainsail study, de Morrée et al. show that the number of docetaxel cycles administered to a patient is a significant factor contributing to overall survival. These findings warrant further investigation into the standardization of the number of docetaxel cycles administered.
authors.affiliation: a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
authors.forename: Hannah E
authors.initials: HE
authors.lastname: Feinman
authors.affiliation: a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.affiliation: a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000077143:Docetaxel; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant; D043823:Taxoids
chemical_list: D043823:Taxoids; D000077143:Docetaxel
keywords: Docetaxel; MRPC; prostate cancer